Search

Your search keyword '"Audrey Hesbois"' showing total 5 results
Start Over Author "Audrey Hesbois" Publication Year Range Last 50 years
5 results on '"Audrey Hesbois"'

1. Stopping or maintaining oral anticoagulation in patients undergoing photoselective vaporization of the prostate (SOAP) surgery for benign prostate obstruction: study protocol for a multicentre randomized controlled trial

Author

Hélène Charbonneau, Marie Pasquié, Benoit Peyronnet, Aurélien Descazeaud, Nicolas Barry-Delongchamps, Emmanuel Della Negra, Romain Mathieu, Gilles Karsenty, Jean-Alexandre Long, Charles Ballereau, Abdel-Rahmène Azzouzi, Benjamin Pradère, Franck Bruyère, Georges Fournier, Souhil Lebdai, Jehanne Calves, Luc Corbel, Sébastien Vincendeau, Gaelle Fiard, Caroline Thuillier, Jean-Luc Descotes, Pierre Colin, Thibaut Culty, Audrey Hesbois, Valerie Fuzier, Nicolas Savy, Atul Pathak, Pierre Albaladejo, Charles Marc Samama, Felipe Guerrero, and Vincent Misraï

Subjects
Benign prostatic obstruction, GreenLight, Laser, Oral anticoagulation, Complications, Medicine (General), R5-920
Abstract

Abstract Background Lower urinary tract symptoms related to benign prostatic obstruction (BPO) are frequent in men aged > 50 years. Based on the use of innovative medical devices, a number of transurethral ablative techniques have recently been developed for the surgical treatment of BPO. In recent years, GreenLight photoselective vaporization of the prostate (PVP) has been considered as a non-inferior alternative to transurethral resection of the prostate. The GreenLight PVP is usually considered as an interesting surgical option for patients treated via oral anticoagulants (OACs) with regard to its haemostatic properties. The aim of this study was to assess the impact of maintaining OAC treatment in patients undergoing PVP. Methods This study is a multicentre, open-label, randomized controlled trial (RCT) designed to show the non-inferiority of PVP surgery in patients with BPO treated with OACs. This study is designed to enrol 386 OAC-treated patients (treated with vitamin K antagonists and direct oral anticoagulants) who are undergoing PVP for BPO. Patients will be randomized (1:1) to either maintain or stop OAC treatment during the perioperative course. The intervention group will maintain OAC treatment until the day before surgery and resume OAC treatment the day after surgery, whereas the control group will stop OAC treatment (with or without low-molecular-weight heparin bridging therapy) according to the anaesthesia guidelines. The primary outcome of interest to be assessed is the 30-day complications rate according to the Clavien-Dindo classification. The secondary endpoint will examine the 30-day rate of haemorrhagic and thrombotic events. This study will provide 80% power to show non-inferiority, defined as not worse than a 10% (non-inferiority margin) inferior change in the proportion of patients with good outcomes (Clavien-Dindo score

Published
2018
Full Text
View/download PDF

2. Stopping or maintaining oral anticoagulation in patients undergoing photoselective vaporization of the prostate (SOAP) surgery for benign prostate obstruction: study protocol for a multicentre randomized controlled trial

Author

L. Corbel, Emmanuel Della Negra, Abdel-Rahmène Azzouzi, Marie Pasquie, Sébastien Vincendeau, Valerie Fuzier, Franck Bruyère, Benoit Peyronnet, Benjamin Pradere, Atul Pathak, Georges Fournier, Aurélien Descazeaud, Thibaut Culty, Hélène Charbonneau, Pierre Albaladejo, Gilles Karsenty, C. Thuillier, Audrey Hesbois, Gaelle Fiard, Jean-Luc Descotes, Souhil Lebdai, C. Ballereau, Nicolas Savy, Nicolas Barry-Delongchamps, J. Calves, Vincent Misrai, Romain Mathieu, Pierre Colin, Charles Marc Samama, Felipe Guerrero, Jean-Alexandre Long, Clinique Pasteur [Toulouse], Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'urologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Privé des Côtes d'Armor (HPCA), Chirurgie urologique et transplantation rénale [Hôpital de la Conception - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Gestes Medico-chirurgicaux Assistés par Ordinateur (TIMC-IMAG-GMCAO), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Service d'urologie [CHU Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service d'urologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Mathématiques de Toulouse UMR5219 (IMT), Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), Techniques pour l'Evaluation et la Modélisation des Actions de la Santé (TIMC-IMAG-ThEMAS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Service d'urologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA), Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10

Subjects
Male, medicine.medical_specialty, Time Factors, Complications, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Prostatic Hyperplasia, 030232 urology & nephrology, Oral anticoagulation, Administration, Oral, Medicine (miscellaneous), Laser, Equivalence Trials as Topic, Drug Administration Schedule, law.invention, Study Protocol, 03 medical and health sciences, 0302 clinical medicine, Lower Urinary Tract Symptoms, Randomized controlled trial, law, Prostate, Lower urinary tract symptoms, medicine, Humans, Multicenter Studies as Topic, Pharmacology (medical), Transurethral resection of the prostate, lcsh:R5-920, business.industry, Anticoagulants, GreenLight, Perioperative, Evidence-based medicine, Heparin, medicine.disease, Confidence interval, 3. Good health, Surgery, Treatment Outcome, medicine.anatomical_structure, 030220 oncology & carcinogenesis, France, Laser Therapy, Benign prostatic obstruction, lcsh:Medicine (General), business, medicine.drug
Abstract

Lower urinary tract symptoms related to benign prostatic obstruction (BPO) are frequent in men aged > 50 years. Based on the use of innovative medical devices, a number of transurethral ablative techniques have recently been developed for the surgical treatment of BPO. In recent years, GreenLight photoselective vaporization of the prostate (PVP) has been considered as a non-inferior alternative to transurethral resection of the prostate. The GreenLight PVP is usually considered as an interesting surgical option for patients treated via oral anticoagulants (OACs) with regard to its haemostatic properties. The aim of this study was to assess the impact of maintaining OAC treatment in patients undergoing PVP. This study is a multicentre, open-label, randomized controlled trial (RCT) designed to show the non-inferiority of PVP surgery in patients with BPO treated with OACs. This study is designed to enrol 386 OAC-treated patients (treated with vitamin K antagonists and direct oral anticoagulants) who are undergoing PVP for BPO. Patients will be randomized (1:1) to either maintain or stop OAC treatment during the perioperative course. The intervention group will maintain OAC treatment until the day before surgery and resume OAC treatment the day after surgery, whereas the control group will stop OAC treatment (with or without low-molecular-weight heparin bridging therapy) according to the anaesthesia guidelines. The primary outcome of interest to be assessed is the 30-day complications rate according to the Clavien-Dindo classification. The secondary endpoint will examine the 30-day rate of haemorrhagic and thrombotic events. This study will provide 80% power to show non-inferiority, defined as not worse than a 10% (non-inferiority margin) inferior change in the proportion of patients with good outcomes (Clavien-Dindo score

Published
2018
Full Text
View/download PDF

3. Bloc neuroaxiaux chez la parturiente obèse

Author

Magali Heintzelmann, Régis Fuzier, Vincent Schtahaups, Valérie Fuzier, and Audrey Hesbois

Subjects
Anesthesiology and Pain Medicine, Emergency Medicine, Emergency Nursing
Abstract

Resume L’obesite chez la parturiente est definie par un IMC « avant la grossesse » ≥ 30 kg/m2. Chez la parturiente obese la morbi-mortalite au cours de la grossesse (hypertension, macrosomie, dystocie des epaules, cesarienne urgente…) est correlee a l’IMC. Une prise en charge multidisciplinaire par des equipes experimentees, l’existence de moyens adaptes et une programmation de l’accouchement sont indispensables. La mise en place precoce d’une peridurale est recommandee pour l’analgesie au cours du travail, bien qu’elle soit techniquement plus difficile (echec, multiples tentatives, faux positifs…) La peridurale doit etre fiable du fait du risque de cesarienne pour dystocie, afin d’eviter une anesthesie generale (intubation difficile). Pour la cesarienne programmee, la rachianesthesie est la meilleure option avec une dose minimale de 10 mg de bupivacaine (+ opiaces). La peri rachianesthesie combinee ou la rachianesthesie continue sont des alternatives interessantes qui doivent etre evaluees.

Published
2015
Full Text
View/download PDF

5. Delayed Horner's syndrome during a continuous infraclavicular brachial plexus block

Author

Arlette Vandesteene, Jean-Corentin Salengros, Audrey Hesbois, Pierre Pandin, Edgard Engelman, and Catherine Jacquot

Subjects
Adult, medicine.medical_specialty, Humeral Fractures, Horner Syndrome, Side effect, Analgesic technique, Fracture Fixation, Internal, Fracture fixation, medicine, Humans, Brachial Plexus, Ropivacaine, Anesthetics, Local, S syndrome, business.industry, Nerve Block, Amides, Surgery, Infraclavicular brachial plexus block, Anesthesiology and Pain Medicine, Anesthesia, Anxiety, Female, medicine.symptom, business, Radius Fractures, Elbow Injuries, Brachial plexus, medicine.drug, Anesthesia, Local
Abstract

Horner's syndrome is a potential, albeit rare, feature of continuous infraclavicular brachial plexus local anesthetics infusion, mainly the result of anatomical considerations. Horner's syndrome may be described as an "unpleasant side effect" because it has no clinical consequences in itself. Nevertheless, patient discomfort and anxiety may reduce acceptance of the analgesic technique. Reassurance and close clinical monitoring of the patient are essential to enhance patient's safety and acceptance of the technique.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results